| • BioBlurb • Clinical Trials and the Financial Markets • E-Discovery and Digital Evidence Case Digest • How to Get a Job and Grow Your Practice • ABA Member Advantage Benefits • Proposed Patent Case Legislation Learn about Section • Computer Forensic Resolution Has Impact in North Carolina • Highlight Section Involvement • Leverage The SciTech Lawyer Electronic Archives • Nominees for Section Officers and Council Positions • Resources for Student Members • Student Opportunity at 2009 ABA Annual Meeting
2nd National Conference on Employment of Lawyers with Disabilities
   The SciTech e-Merging News is published quarterly as a Section member benefit. Click here to join the Section. The material published reflects the views of the authors and has not been approved by the Section of Science & Technology Law, the House of Delegates or the Board of Governors of the ABA. © 2009 American Bar Association. All rights reserved. | In This Issue bioblurb by Lisa M. von Biela
A MESSAGE FROM YOUR EDITOR: We've got it all this week-everything including red, glow-in-the-dark beagle pups. I can see the advantage in that. Have the right UV light going, and you'll never trip on your dog in the dark again. Could save some broken bones.
1. Hospitals replace DNR with "Allow Natural Death." OK, this is a little more Health Law than Biotech, but . . . 2. Institute of Medicine calls on doctors to stop taking industry gifts. The chorus is growing . . .
1. Wyeth decision opens the floodgates for failure to warn suits. 2. McKesson drug price fraud settlement wins initial approval from court.
1. Autism tied to older moms, breech birth. 2. Gene alterations associated with response to anthracycline therapy for breast cancer. 3. Discovery of key genetic factors that drive the process of generating new heart cells. BIOTECH RESEARCH/SCIENCE: 1. Drug library helps in developing new remedies from old. 2. Nanoparticles may help to attack cancer more directly. Bucky Balls, anyone? 3. Gene-laden bubbles grow new blood vessels.
1. Utah rolls out first U.S. open source disease tracker. Gee, just in time with this swine flu business going on . . . 2. Report recommends certain priorities when implementing electronic health records. 3. DTC genetic tests banned in Germany. 4. Microsoft aims to help scientists move past Excel, make sense of gene data overload. Wonder what name they'll come up with? Genome 2010? PowerDNAPoint? ChromasomeServer? Sorry, could not help myself!
1. Recession puts squeeze on hospital IT projects. 2. FDA approves J&J's rheumatoid arthritis drug golimumab-expected to be a blockbuster. I know, that looks like a major typo on my part, but it is not.
1. Republican senator pushes for biotech funding, new agency. 2. Sebelius sworn in as HHS secretary. 3. Two senators introduce bill on FDA inspection of drug plants. PATENT/IP ISSUES: 1. Watson and Novartis battle over Enablex patent. 2. Sanofi loses appeal on Lovenox patent. What is this? The meds all need to end in "x" this week!
1. FDA allows uncleared uses of flu drugs and tests. Oxymoron of the week: authorized off-label use. 2. "Pharma-scolds" scolded. I can see the fingers wagging now! 3. Acetaminophen products to contain stronger warnings on labels in U.S. WEIRD NEWS: 1. South Korean experts claim to have cloned glowing dogs. They look like normal beagles, but put them under UV light and they glow red. What *will* they think of next? Hot dog! BioBlurb is a weekly member benefit of the Biotechnology Law Committee. Click here to join the Biotechnology Law Committee for free today! Lisa M. von Biela
Your e-mail address will only be used within the ABA and its entities. We do not sell or rent e-mail addresses to anyone outside the ABA. Update your profile | Unsubscribe | Privacy Policy American Bar Association | 321 N Clark | Chicago, IL 60654 | 1-800-285-2221 |
This book provides you with a legal and practical approach to the new world of digital information. It has been described as a must have for litigation lawyers, corporate counsel and records managers who want to understand how to appropriately handle the digital information of an enterprise. 
This book clearly explains and discusses 13 applied scientific disciplines in jargon-free language that is specifically geared toward lawyers. If you are a lawyer who is ever called upon to defend, proceed against, examine, cross-examine or even consult a scientist, this book is for you. 